iifl-logo-icon 1

Raymed Labs Ltd Share Price

2.5
(4.60%)
Jul 8, 2024|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open2.5
  • Day's High2.5
  • 52 Wk High2.5
  • Prev. Close2.39
  • Day's Low2.5
  • 52 Wk Low2.08
  • Turnover (lac)0
  • P/E0
  • Face Value10
  • Book Value-5.64
  • EPS0
  • Mkt. Cap (Cr.)1.07
  • Div. Yield0
No Records Found

Raymed Labs Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

2.5

Prev. Close

2.39

Turnover(Lac.)

0

Day's High

2.5

Day's Low

2.5

52 Week's High

2.5

52 Week's Low

2.08

Book Value

-5.64

Face Value

10

Mkt Cap (₹ Cr.)

1.07

P/E

0

EPS

0

Divi. Yield

0

Raymed Labs Ltd Corporate Action

2 Aug 2023

12:00 AM

AGM

Announcement Date: 02 Aug, 2023

arrow

13 May 2024

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

2 Aug 2023

12:00 AM

BookCloser

arrow

Raymed Labs Ltd NEWS AND UPDATE

No data found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Raymed Labs Ltd SHAREHOLDING SNAPSHOT

20 Jul, 2024|08:17 AM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 28.36%

Foreign: 0.00%

Indian: 28.36%

Non-Promoter- 0.96%

Institutions: 0.95%

Non-Institutions: 70.67%

Custodian: 0.00%

Share Price

Raymed Labs Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Loading...
Y/e 31 Mar( In .Cr)Mar-2023Mar-2022Mar-2021Mar-2020

Equity Capital

4.27

4.27

4.27

4.27

Preference Capital

0

0

0

0

Reserves

-6.58

-6.41

-6.33

-6.26

Net Worth

-2.31

-2.14

-2.06

-1.99

Minority Interest

View Balance Sheet
Loading...
Y/e 31 Mar( In .Cr)Mar-2021Mar-2020Mar-2018Mar-2017

Revenue

0

0

0

0

yoy growth (%)

0

0

0

0

Raw materials

0

0

0

0

As % of sales

0

0

0

0

Employee costs

-0.02

-0.01

-0.01

-0.01

View Profit & Loss
Loading...
Y/e 31 Mar( In .Cr)Mar-2021Mar-2020Mar-2018Mar-2017

Profit before tax

-0.06

-0.02

-0.02

-0.02

Depreciation

0

0

0

0

Tax paid

0

0

0

0

Working capital

0.08

-0.06

-0.04

0

Other operating items

View Cash Flow
Loading...
Y/e 31 MarMar-2021Mar-2020Mar-2018Mar-2017

Growth matrix (%)

Revenue growth

0

0

0

0

Op profit growth

129.2

-8.19

3.76

26.28

EBIT growth

196.15

-16.65

3.01

79.79

Net profit growth

23.59

-1.66

13.34

33.05

View Ratios

No Record found

Raymed Labs Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceuticals Industries Ltd

SUNPHARMA

1,593.65

125.293,82,370.02867.60.855,536.9998.75

Divis Laboratories Ltd

DIVISLAB

4,582.3

77.221,21,645.675310.652,259507.93

Cipla Ltd

CIPLA

1,506.05

32.741,21,616.251,038.40.563,444.92346.41

Zydus Lifesciences Ltd

ZYDUSLIFE

1,185.3

34.71,19,268.911,405.20.253,172.6156.19

Dr Reddys Laboratories Ltd

DRREDDY

6,665.1

25.951,11,193.661,034.80.65,081.81,458.96

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Raymed Labs Ltd

Management

Register Office

Registrar Office

Whole Time Director & CFO

Ajai Goyal

Director

Nisha Goyal

Independent Director

Harsh Prabhakar

Independent Director

Poonam Sharma

Company Sec. & Compli. Officer

Shreya Dave

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Summary

Raymed Labs Ltd was established in the year 1994 as a pharmaceutical company with emphasis on injectables with state of the art manufacturing facilities on Dehradun Road, Saharanpur, UP. The Company embarked on a new and exciting phase of its growth journey. As a widely operational pharmaceutical company, it proved excellence in the competitive ophthalmology industry with its robust marketing infrastructure across the geographies.Raymed created an integrated multi-technology capability to manufacture all types of formulations with innovative and advanced technologies focusing into Preservative free Ophthalmic dosage specially for Conjunctivitis and Glaucoma Patient care, Various other formulations have been converted from suspension to solution which helps in the effective absorption, penetration and better patience compliance.Highly skilled technicians operate multiple manufacturing facilities with the world class technology, having ultramodern equipment and machineries for manufacturing formulations in wide range of dosage forms. All are facilities are certified with WHO-GMP, ISO 9001:2008 and various International accreditations like ANVISA-Brazil, NAFDAC-Nigeria, FDB-Ghana, PMPB-Malawi amongst others. Expanding with time the Company has a comprehensive range of over 80 products, Raymed is a trademark owner of ophthalmic solution (eye drops), antioxidant capsules and tablets.
Read More

Company FAQs

What is the Raymed Labs Ltd share price today?

Down Arrow

The Raymed Labs Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is Rs.₹2.5 today.

What is the Market Cap of Raymed Labs Ltd?

Down Arrow

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Raymed Labs Ltd is ₹1.07 Cr. as of 08 Jul ‘24

What is the PE and PB ratio of Raymed Labs Ltd?

Down Arrow

The PE and PB ratios of Raymed Labs Ltd is 0 and -0.44 as of 08 Jul ‘24

What is the 52 Week High and Low of Raymed Labs Ltd?

Down Arrow

The 52-week high/low is the highest and lowest price at which a Raymed Labs Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Raymed Labs Ltd is ₹2.08 and ₹2.5 as of 08 Jul ‘24

What is the CAGR of Raymed Labs Ltd?

Down Arrow

Raymed Labs Ltd's CAGR for 5 Years at 0.82%, 3 Years at 36.64%, 1 Year at 11.61%, 6 Month at 1.63%, 3 Month at 4.60% and 1 Month at 4.60%.

What is the shareholding pattern of Raymed Labs Ltd?

Down Arrow

The shareholding pattern of Raymed Labs Ltd is as follows:
Promoters - 28.36 %
Institutions - 0.96 %
Public - 70.68 %

Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.